| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Apr―07 |
Disruption of healthcare delivery and clinical trial operations during COVID-19: Lessons learned, planning for solutions |
Veena Shridhar Jaguste |
| 2 |
[GO] |
2025―Jan―31 |
Comparison of pre-COVID-19 pandemic, lockdown, and postlockdown participant adherence in a phase IV clinical trial for the treatment of postexposure rabies prophylaxis |
Vijaya Laxman Chaudhari, Akshay Sanjay Argade, Saee Sudesh Hinglaspurkar, Nithya Jaideep Gogtay |
| 3 |
[GO] |
2024―Jan―09 |
Effectiveness of partial COVID-19 vaccination on the outcome of hospitalized COVID-19 patients during the second pandemic in India |
Sajal De, Dibakar Sahu, Diksha Mahilang, Ranganath T. Ganga, Ajoy Kumar Behera |
| 4 |
[GO] |
2023―Nov―17 |
Trends of different inflammatory markers and clinical outcomes in hospitalized COVID-19 patients |
Srikanth Krishnamurthy, Nandagopal Velayuthaswamy, Jaymohan Unnithan, Nagarajan Srinivasan, Shobana Balasubramaniam, Ramesh Jagannathan |
| 5 |
[GO] |
2023―Okt―31 |
Perception and practices on COVID-19 vaccination and booster dose acceptability among health-care workers - A questionnaire-based study |
Nivethia K. Rathinakumar, Anandabaskar Nishanthi, Shanthi Manickam |
| 6 |
[GO] |
2023―Okt―31 |
Impact of the COVID pandemic on functioning of the institutional ethics committee: A comparison study |
Yashashri Chandrakant Shetty, Urmila Mukund Thatte, Amitrajit Pal, Janhavi Katkar |
| 7 |
[GO] |
2023―Okt―06 |
Characteristics, attitudes, and the odds for positive attitude toward clinical trial: A study on Indonesian COVID-19 vaccine trial participants |
Nani Maharani, Nuvi Gustriawanto, YettyM Nency, Endang Mahati, GlennF Yeremia, DimasT Anantyo, et al. (+4) Rebriarina Hapsari, Mulyono Mulyono, SetyoG Pramudo, Nur Farhanah |
| 8 |
[GO] |
2022―Nov―02 |
Experience of the selected Ethics Committee of Pune city regarding the review of COVID-19 protocols during the pandemic |
SonopantG Joshi, AbhijeetAshok Safai, SamirSumant Barve |
| 9 |
[GO] |
2022―Jul―27 |
Impact of COVID-19 on management of clinical trials and the potential mitigating strategies |
Vijaykumar Gawali, Parag Sarve, Heena Ali, Sarvajnya Tattu, Charulata Chetule |
| 10 |
[GO] |
2022―Jun―30 |
Severe acute respiratory syndrome coronavirus-2 IgG antibody response to coronavirus disease 2019 vaccination in South Indian health-care professionals with and without coronavirus disease 2019 exposure |
Viswanathan Mohan, Ramamoorthy Jayashri, Kaliyaperumal Velmurugan, Chakrapani Jayanthi, RanjitMohan Anjana, Ranjit Unnikrishnan |
| 11 |
[GO] |
2022―Apr―05 |
A narrative review of the challenges, ethical frameworks, and guidelines in the setting of COVID-19 healthcare and research |
Uma Kulkarni, Naheeda Hamza |
| 12 |
[GO] |
2022―Jan―11 |
Functioning of Institutional Ethics Committees During the COVID-19 pandemic: An opinion survey |
Shatavisa Mukherjee, ShamboSamrat Samajdar, Rohan Tripathi, SantanuKumar Tripathi |
| 13 |
[GO] |
2022―Jan―11 |
An evaluation of the minutes of subject expert committee meetings of novel COVID-19 proposals |
UrmilaMukund Thatte, JeffreyPradeep Raj, Ambika Mamde, Keya Ganatra, NithyaJaideep Gogtay |
| 14 |
[GO] |
2022―Jan―05 |
Clinical trials and Consolidated Standards of Reporting Trials: Continuing concerns of compliance in COVID-19 era |
Arun Bhatt |
| 15 |
[GO] |
2021―Sep―18 |
Perception of Indian citizens toward the available COVID-19 vaccines: Need to create increased awareness |
Akila Prashant, AnaghaHari Bharadwaj, ShobhaChikkavaddaragudi Ramachandra, Abhijith Devaraju, SumaM Nataraj, Prashant Vishwanath |
| 16 |
[GO] |
2021―Jul―07 |
A survey to assess the impact of the COVID-19 pandemic and the resultant lockdown measures on the ongoing clinical trials in India |
Jayanti Gupta, RakeshN Dadhania |
| 17 |
[GO] |
2021―Jan―19 |
Declaration of conflict of interest for reviewers in time of COVID-19 should be mandatory |
Francesco Chirico, NicolaLuigi Bragazzi |
| 18 |
[GO] |
2020―Okt―28 |
Indian Regulatory Update-2 during the COVID-19 pandemic |
Amita Bhave |
| 19 |
[GO] |
2020―Okt―06 |
Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness |
Arun Bhatt |
| 20 |
[GO] |
2020―Jul―07 |
Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice |
Arun Bhatt |
| 21 |
[GO] |
2020―Jul―06 |
COVID-19 effect on clinical research: Single-site risk management experience |
FatmaSoliman Elsayed Ebeid |
| 22 |
[GO] |
2020―Jul―06 |
Indian regulatory update during the COVID-19 pandemic |
AmitaChandan Bhave |
| 23 |
[GO] |
2020―Jul―06 |
Addressing challenges due to the COVID-19 pandemic - A site and investigator perspective |
NithyaJaideep Gogtay, Priya Ranganathan, Deepa Nair |
| 24 |
[GO] |
2020―Jul―06 |
Real-world data in COVID-19 pandemic: An essential unmet health-care need |
Arun Bhatt |
| 25 |
[GO] |
2020―Jul―06 |
Prerequisite of doing clinical trial with drugs in COVID-19 patients: Situational experience |
Pugazhenthan Thangaraju, Atul Jindal |
| 26 |
[GO] |
2020―Jul―06 |
Challenges and opportunities for sponsors in conducting clinical trials during a pandemic |
Sanish Davis, Seema Pai |
